MapLight Therapeutics Reports Third Quarter 2026 Results and Updates Progress on ML-007C-MA Clinical Programs

MapLight Therapeutics reported Q3 2026 results, with $463.4M in cash. It plans ZEPHYR-2 Phase 3 trial for ML-007C-MA in schizophrenia, with results expected in 2028. Phase 2 VISTA trial for Alzheimer’s disease psychosis is ongoing, with results expected in 2H 2027. The company raised $150M in August 2026 to support these trials.

Original reporting
Published Nov 16, 2026, 12:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 12:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
MapLight Therapeutics Reports Third Quarter 2026 Results and Updates Progress on ML-007C-MA Clinical Programs — source image
Decision brief

The 30-second read

$MPLTBearishMed
01

Why it matters

Earnings release provides new guidance on cash runway and trial timelines, influencing valuation and risk assessment.

02

Market read

First‑time Q3 earnings data for MPLT, with cash position and trial milestones, relevant for biotech investors.

03

What to watch

Fast Track designation for ML‑007C‑MA could accelerate regulatory timeline.

Relevance 7/10Novelty 7/10Timing: post-market today

Background

MapLight Therapeutics (Nasdaq:MPLT) is a clinical‑stage biopharma focused on CNS disorders, reporting its third‑quarter financials and trial updates.

Company-level read

Ticker impact

$MPLTBearishHigh confidence
Context

MapLight Therapeutics reported Q3 2026 results, cash position, and upcoming clinical milestones, providing fresh earnings data and guidance.

Expected impact

potential downside pressure as investors price in net loss and higher R&D spend

Evidence & confidence

The company posted a $51.6M net loss and higher expenses, but disclosed $463M cash to fund trials through 2028.

Market effects

Highlights continued cash‑intensive development in CNS biotech, may affect peer valuations.

US‑listed biotech sector could see modest pullback.

Limited to investors tracking small‑cap biotech pipelines.

Counterpoint

Cash runway to 2028 may offset short‑term loss concerns, supporting a hold.

Key entities

  • MapLight Therapeutics

    Clinical‑stage biopharma developing ML‑007C‑MA and ML‑004.

Related articles

$MPLTMed

MapLight Therapeutics 3Q 2026: EPS ($0.97) — 10-Q Summary

MapLight Therapeutics reported a wider net loss of $51.62M in 3Q 2026, up 75.5% YoY, due to increased R&D and clinical trial expenses. Diluted EPS was ($0.97). The company plans a Phase 3 schizophrenia trial and expects Alzheimer’s disease psychosis trial results in 2H 2027. Cash reserves of $463.4M are expected to last through 2028.

$MPLTHigh

MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

MapLight Therapeutics, Inc. (MPLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update Planning underway for ZEPHYR-2, the confirmatory Phase 3 trial of ML-007C-MA in schizophrenia, with topline results expected in the second half 2027 Enrollment ongoing in

$MPLTMed

MapLight Therapeutics, Inc. (MPLT): Reported positive results from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, supporting advancement into a Phase 3…

MapLight Therapeutics, Inc. (MPLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Reported positive results from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, supporting advancement into a Phase 3 ZEPHYR-2 trial Continued advancement of ML-007C-MA in ADP, with enrollment ongoing in the Phase 2 VISTA trial and